14.05

4.29% -0.63

Pre-market: 14.05

Dyne Therapeutics Inc (DYN)

Overview News Price History Option Chain Financials Why DYN Down? Discussions Forecast

Dyne Therapeutics Inc stock is traded at $14.05, with a volume of 1.83M. It is down -4.29% in the last 24 hours and up +5.80% over the past month. Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Previous Close:

$14.68

Open:

$14.13

24h Volume:

1.83M

Relative Volume:

0.69

Market Cap:

$2.00B

Revenue:

Net Income/Loss:

$-412.89M

P/E Ratio:

-3.6399

EPS:

-3.86

Net Cash Flow:

$-361.93M

1W Performance:

+7.58%

1M Performance:

+5.80%

6M Performance:

+101.29%

1Y Performance:

-56.85%

1-Day Range:

$13.75

$14.29

1-Week Range:

$12.43

$15.22

52-Week Range:

$6.36

$35.90

Dyne Therapeutics Inc Stock (DYN) Company Profile

Name

Dyne Therapeutics Inc

Sector

Healthcare (1140)

Industry

Biotechnology (637)

Phone

(781) 786-8230

Address

1560 TRAPELO ROAD, WALTHAM

Employee

206

Twitter

Next Earnings Date

2024-11-04

Latest SEC Filings

DYN's Discussions on Twitter

Compare DYN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DYN Dyne Therapeutics Inc	14.05	2.09B	0	-412.89M	-361.93M	-3.86
VRTX Vertex Pharmaceuticals Inc	407.79	106.37B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	460.46	59.90B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	564.63	60.40B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	796.92	49.56B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	320.10	36.88B	4.56B	-176.77M	225.30M	-1.7177

Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-10-25	Downgrade	Oppenheimer	Outperform → Perform
Aug-25-25	Upgrade	Raymond James	Outperform → Strong Buy
Jun-24-25	Initiated	Bernstein	Mkt Perform
Jun-11-25	Resumed	Raymond James	Outperform
Jun-02-25	Resumed	Oppenheimer	Outperform
May-29-25	Initiated	Evercore ISI	Outperform
Mar-12-25	Initiated	BMO Capital Markets	Outperform
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Dec-13-24	Initiated	Robert W. Baird	Outperform
Nov-26-24	Initiated	RBC Capital Mkts	Outperform
Oct-24-24	Downgrade	JP Morgan	Overweight → Neutral
May-21-24	Reiterated	Chardan Capital Markets	Buy
Apr-30-24	Initiated	Morgan Stanley	Overweight
Feb-20-24	Initiated	H.C. Wainwright	Buy
Feb-27-23	Upgrade	Raymond James	Outperform → Strong Buy
Feb-15-23	Initiated	Oppenheimer	Outperform
Jan-26-23	Initiated	Guggenheim	Buy
Jul-20-22	Initiated	Chardan Capital Markets	Buy
Jul-12-22	Initiated	Raymond James	Outperform
Oct-12-20	Initiated	JP Morgan	Overweight
Oct-12-20	Initiated	Jefferies	Buy
Oct-12-20	Initiated	Piper Sandler	Overweight
Oct-12-20	Initiated	Stifel	Buy

View All

Dyne Therapeutics Inc Stock (DYN) Latest News

02:19 AM

Dyne Therapeutics Inc.’s volatility index tracking explainedCEO Change & AI Based Buy and Sell Signals - newser.com

02:19 AM

01:32 AM

Is Dyne Therapeutics Inc. stock gaining market shareJuly 2025 Drop Watch & Daily Profit Focused Stock Screening - newser.com

01:32 AM

Oct 12, 2025

What recovery options are there for Dyne Therapeutics Inc.July 2025 Levels & Low Risk Entry Point Guides - newser.com

Oct 12, 2025

Oct 11, 2025

Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down After Analyst Downgrade - MarketBeat

Oct 11, 2025

Oppenheimer Downgrades Dyne Therapeutics (NASDAQ:DYN) to Market Perform - MarketBeat

Oct 11, 2025

Oct 10, 2025